logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Inc. (CNAT) Is Up Sharply On Phase 2 Study Results

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Tuesday that its Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 vs. placebo. Multiple additional liver disease biomarkers achieved statistically significant reductions vs. placebo.

Conatus Pharmaceuticals has gapped open sharply higher Wednesday morning and is now up 0.83 at $3.70 on the highest volume in over 3 months. The stock has jumped to a month and a half high and has re-crossed its 50-day moving average.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT